High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation

Bone Marrow Transplantation

Volumn 46, Issue 1, 2011, Pages 20-26

  Long Boyle, J R ^a,b   Green, K G ^b   Brunstein, C G ^a   Cao, Q ^c   Rogosheske, J ^b   Weisdorf, D J ^a   Miller, J S ^a   Wagner, J E ^a   McGlave, P B ^a   Jacobson, P A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

F ara A; fludarabine; nonmyeloablative; pharmacokinetics; TRM

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG HALF LIFE; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORTALITY; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PHARMACODYNAMICS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; WHOLE BODY RADIATION;

ADULT; AGED; DRUG MONITORING; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEUTROPHIL INFILTRATION; PRODRUGS; RENAL INSUFFICIENCY; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; VIDARABINE; VIDARABINE PHOSPHATE; YOUNG ADULT;

EID: 78651350124     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.53     Document Type: Article

References (43)

1. Baron F, Storb R. Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders. Mol Ther 2006; 13: 26-41.
2. Brockman RW, Cheng YC, Schabel Jr FM, Montgomery JA. Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl- 2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res 1980; 40: 3610-3615.
3. Dow LW, Bell DE, Poulakos L, Fridland A. Differences in metabolism and cytotoxicity between 9-beta-D arabinofuranosyladenine and 9-beta-D- arabinofuranosyl-2-fluoroadenine in human leukemic lymphoblasts. Cancer Res 1980; 40: 1405-1410.
4. Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003; 102: 2021-2030.
5. Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Miller JS, Blazar BR et al. Umbilical cord blood transplantation after non-myeloablative conditioning: Impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007; 110: 3064-3070.
6. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: The updated M D. Anderson Cancer Center experience. Haematologica 2008; 93: 257-264.
7. Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Semin Oncol 1990; 17(5 Suppl 8): 3-17.
8. Danhauser L, Plunkett W, Liliemark J, Gandhi V, Iacoboni S, Keating M. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9- beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. Leukemia 1987; 1: 638-643.
9. Danhauser L, Plunkett W, Keating M, Cabanillas F. 9-beta- Darabinofuranosyl- 2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother Pharmacol 1986; 18: 145-152.
10. Avramis VI, Champagne J, Sato J, Krailo M, Ettinger LJ, Poplack DG et al. Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients. Cancer Res 1990; 50: 7226-7231.
11. Avramis VI, Wiersma S, Krailo MD, Ramilo-Torno LV, Sharpe A, Liu-Mares W et al. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Clin Cancer Res 1998; 4: 45-52.
12. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002; 41: 93-103.
13. Lichtman SM, Etcubanas E, Budman DR, Eisenberg P, Zervos G, D'Amico P et al. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: A prospective dose adjustment study. Cancer Invest 2002; 20: 904-913.
14. Hersh MR, Kuhn JG, Phillips JL, Clark G, Ludden TM, Von Hoff DD. Pharmacokinetic study of fludarabine phosphate (NSC 312887). Cancer Chemother Pharmacol 1986; 17: 277-280.
15. Hutton JJ, Von Hoff DD, Kuhn J, Phillips J, Hersh M, Clark G. Phase I clinical investigation of 9-beta-D-arabinofuranosyl- 2-fluoroadenine 50-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res 1984; 44: 4183-4186.
16. Kuo GM, Boumpas DT, Illei GG, Yarboro C, Pucino F, Burstein AH. Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. Pharmacotherapy 2001; 21: 528-533.
17. Knebel W, Davis Jr JC, Sanders WD, Fessler B, Yarboro C, Pucino F et al. The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis. Pharmacotherapy 1998; 18: 1224-1229.
18. Malspeis L, Grever MR, Staubus AE, Young D. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. Semin Oncol 1990; 17(5 Suppl 8): 18-32.
19. Bonin M, Pursche S, Bergeman T, Leopold T, Illmer T, Ehninger G et al. F-ara-A pharmacokinetics during reducedintensity conditioning therapy with fludarabine and busulfan. Bone Marrow Transplant 2007; 39: 201-206.
20. Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003; 102: 820-826.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
22. Weisdorf DJ, Snover DC, Haake R, Miller WJ, McGlave PB, Blazar B et al. Acute upper gastrointestinal graft-versus-host disease: Clinical significance and response to immunosuppressive therapy. Blood 1990; 76: 624-629.
23. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
24. Anon. Guidelines for Industry: Pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling. Center for Drug Evaluation and Research: Rockville, MD, 1998.
25. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)- specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
26. Majhail NS, Brunstein CG, McAvoy S, DeFor TE, Al- Hazzouri A, Setubal D et al. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant 2008; 14: 985-992.
27. Anonymous. Product Information: Fludara (R) (fludarabine phosphate) For Injection. Berlex Laboratories: Richmond, California, 2002.
28. McCune JS, Batchelder A, Guthrie KA, Witherspoon R, Appelbaum FR, Phillips B et al. Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: A phase II trial in patients with hematologic malignancy. Clin Pharmacol Ther 2009; 85: 615-622.
29. McCune JS, Salinger DH, Vicini P, Oglesby C, Blough DK, Park JR. Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: A report from the Children's Oncology Group. J Clin Pharmacol 2009; 49: 88-102.
30. Ding X, Herzlich AA, Bishop R, Tuo J, Chan CC. Ocular toxicity of fludarabine: A purine analog. Expert Rev Ophthalmol 2008; 3: 97-109.
31. Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs: A review. J Clin Oncol 1994; 12: 2216-2228.
32. Narimatsu H, Miyamura K, Iida H, Hamaguchi M, Uchida T, Morishita Y. Early central nervous complications after umbilical cord blood transplantation for adults. Biol Blood Marrow Transplant 2009; 15: 92-100.
33. Gonzalez H, Bolgert F, Camporo P, Leblond V. Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP). Hematol Cell Ther 1999; 41: 183-186.
34. Saumoy M, Castells G, Escoda L, Mares R, Richart C C, Ugarriza A. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine. Leuk Lymphoma 2002; 43: 433-436.
35. Kiewe P, Seyfert S, Korper S, Rieger K, Thiel E, Knauf W. Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy. Leuk Lymphoma 2003; 44: 1815-1818.
36. Vidarsson B, Mosher DF, Salamat MS, Isaksson HJ, Onundarson PT. Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease. Am J Hematol 2002; 70: 51-54.
37. Neff RT, Hurst FP, Falta EM, Bohen EM, Lentine KL, Dharnidharka VR et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 2008; 86: 1474-1478.
38. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: A review. J Neurol 1999; 246: 339-346.
39. Minn AY, Fisher PG, Barnes PD, Dahl GV. A syndrome of irreversible leukoencephalopathy following pediatric allogeneic bone marrow transplantation. Pediatr Blood Cancer 2007; 48: 213-217.
40. Mackey JR, Galmarini CM, Graham KA, Joy AA, Delmer A, Dabbagh L et al. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): Identification of fludarabine-sensitive and -insensitive populations. Blood 2005; 105: 767-774.
41. Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V et al. Pharmacogenetics of deoxycytidine kinase: Identification and characterization of novel genetic variants. J Pharmacol Exp Ther 2007; 323: 935-945.
42. Molina-Arcas M, Marce S, Villamor N, Huber-Ruano I, Casado FJ, Bellosillo B et al. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia 2005; 19: 64-68.
43. Jacobson P, Rogosheske J, Barker JN, Green K, Ng J, Weisdorf D et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther 2005; 78: 486-500.